Free Trial
NASDAQ:PASG

Passage Bio Q2 2025 Earnings Report

Passage Bio logo
$6.38 +0.77 (+13.73%)
Closing price 08/13/2025 04:00 PM Eastern
Extended Trading
$6.52 +0.14 (+2.19%)
As of 08/13/2025 07:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Passage Bio EPS Results

Actual EPS
-$2.96
Consensus EPS
-$4.00
Beat/Miss
Beat by +$1.04
One Year Ago EPS
N/A

Passage Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Passage Bio Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 12, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Passage Bio's Q3 2025 earnings is scheduled for Thursday, August 14, 2025

Passage Bio Earnings Headlines

Passage Bio Reports Q2 2025 Progress and Financials
Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.
See More Passage Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Passage Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Passage Bio and other key companies, straight to your email.

About Passage Bio

Passage Bio (NASDAQ:PASG), a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

View Passage Bio Profile

More Earnings Resources from MarketBeat